Loading…
Maxadilan-simile expression in Nyssomyia neivai, a sandfly vector in an endemic region of Brazil, and its immunogenicity in patients with American tegumentary leishmaniasis
BACKGROUND Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is...
Saved in:
Published in: | Memórias do Instituto Oswaldo Cruz 2018-04, Vol.112 (2) |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | BACKGROUND Maxadilan (Max) is a salivary component in the sandfly
Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral
leishmaniasis. Max has a powerful vasodilatory effect and is a
candidate vaccine that has been tested in experimental leishmaniasis.
Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible
for American tegumentary leishmaniasis (ATL) in Brazil. OBJECTIVE We
searched for Max expression in Ny. neivai and for antibodies against
Max in ATL patients. METHODS cDNA and protein were extracted from the
cephalic segment, including salivary glands, of Ny. neivai and analysed
by polymerase chain reaction, DNA sequencing, and blotting assays. The
results were compared with data obtained from Lu. longipalpis samples.
We quantified antibodies against Max in serum samples from 41 patients
with ATL (31 and 10 with the cutaneous and mucocutaneous forms,
respectively) and 63 controls from the endemic northeastern region of
São Paulo state, using enzyme-linked immunosorbent assay. FINDINGS
Recognition of a Max-simile peptide by specific antibodies confirmed
expression of a Max sequence in Ny. neivai (GenBank EF601123.1).
Compared to controls, patients with ATL presented higher levels of
antibodies against Max (p = 0.004); 24.4% of the patients with ATL and
3.2% of the controls presented anti-Max levels above the cutoff index
(p = 0.014). The anti- Max levels were not associated with the specific
clinical form of ATL, leishmanin skin test response, absence or
presence of amastigotes in histopathologic exam, results of indirect
immunofluorescence testing for leishmaniasis, or duration of cutaneous
form disease. MAIN CONCLUSION High serum anti-Max levels did not
protect patients against ATL, but confirmed previous natural exposure
to Ny. neivai bites in this ATL endemic region. |
---|---|
ISSN: | 1678-8060 |